Mitsubishi UFJ Trust & Banking Corp Acquires 1,936 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Mitsubishi UFJ Trust & Banking Corp grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.5% during the fourth quarter, Holdings Channel reports. The firm owned 79,397 shares of the biopharmaceutical company’s stock after purchasing an additional 1,936 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Alnylam Pharmaceuticals were worth $31,572,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Brighton Jones LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $243,000. Geneos Wealth Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 372.3% in the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 175 shares in the last quarter. Flow Traders U.S. LLC bought a new stake in Alnylam Pharmaceuticals in the second quarter worth $241,000. Daiwa Securities Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after purchasing an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 70,300.0% in the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 703 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Jeffrey V. Poulton sold 2,206 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $722,795.90. Following the sale, the executive vice president directly owned 64,273 shares in the company, valued at $21,059,048.45. The trade was a 3.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 38,656 shares of company stock worth $12,370,696 in the last three months. Company insiders own 0.86% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ALNY shares. Wells Fargo & Company reduced their price target on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 20th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Needham & Company LLC reduced their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Wall Street Zen cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $472.78.

Alnylam Pharmaceuticals Stock Down 0.3%

Shares of ALNY opened at $301.19 on Thursday. The company has a 50-day simple moving average of $320.71 and a 200-day simple moving average of $377.92. The firm has a market capitalization of $40.19 billion, a P/E ratio of 176.13 and a beta of 0.39. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. Alnylam Pharmaceuticals, Inc. has a 52 week low of $245.96 and a 52 week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm’s quarterly revenue was up 84.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.65) EPS. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.75 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.